Treatment-emergent adverse events (TEAEs) in 89 treated patients
| Cohort 1 | Cohort 2 | Total n (%) | |
| TEAEs reported in >10% of subjects | 45 | 33 | 78 (87.6) |
| Cough | 19 | 9 | 28 (31.5) |
| Fatigue | 8 | 10 | 18 (20.2) |
| Dyspnoea | 11 | 5 | 16 (18.0) |
| Upper respiratory tract infection | 9 | 5 | 14 (15.7) |
| Nasopharyngitis | 7 | 6 | 13 (14.6) |
| Bronchitis | 6 | 6 | 12 (13.5) |
| Headache | 8 | 3 | 11 (12.4) |
| Peripheral oedema | 4 | 6 | 10 (11.2) |
| Diarrhoea | 7 | 3 | 9 (10.1) |
| Dizziness | 5 | 4 | 10 (11.2) |
| Nausea | 6 | 4 | 10 (11.2) |
| Urinary tract infection | 5 | 4 | 9 (10.1) |
| Pneumonia | 6 | 2 | 8 (9.0) |
| Idiopathic pulmonary fibrosis exacerbation | 3 | 5 | 8 (9.0) |
| Nasal congestion | 1 | 7 | 8 (9.0) |
| Treatment-emergent serious adverse events# | 13 | 11 | 24 (27.0) |
| Cardiac disorders | 0 | 4 | 4 (4.5) |
| Gastrointestinal disorders | 1 | 0 | 1 (1.1) |
| Infections and infestations | 7 | 3 | 10 (11.2) |
| Pneumonia | 6 | 2 | 8 (9.0) |
| Influenza | 0 | 1 | 1 (1.1) |
| Neoplasms¶ | 0 | 1 | 1 (1.1) |
| Nervous system disorders | 2 | 0 | 2 (2.2) |
| Psychiatric disorders | 1 | 0 | 1 (1.1) |
| Renal and urinary disorders | 0 | 1 | 1 (1.1) |
| Respiratory, thoracic and mediastinal disorders | 5 | 6 | 11 (12.4) |
| Idiopathic pulmonary fibrosis | 2 | 4 | 6 (6.7) |
| Acute respiratory failure | 2 | 0 | 2 (2.2) |
| Dyspnoea | 0 | 1 | 1 (1.1) |
| Epistaxis | 0 | 1 | 1 (1.1) |
| Hypoxia | 0 | 1 | 1 (1.1) |
| Pulmonary hypertension | 0 | 1 | 1 (1.1) |
| Respiratory arrest | 1 | 0 | 1 (1.1) |
| Respiratory failure | 0 | 1 | 1 (1.1) |
| Vascular disorders | 2 | 0 | 2 (2.2) |
TEAEs included medical conditions, signs and symptoms not previously observed in the subject that emerged during the protocol-specified adverse event reporting period. A serious adverse event was defined as any adverse event or suspected adverse reaction that resulted in death, a life-threatening adverse event, inpatient hospitalisation or prolongation of existing hospitalisation, persistent or significant incapacity, or substantial disruption of the ability to conduct normal life functions. #: 24 subjects with serious adverse events; some subjects experienced more than one serious adverse events. ¶: benign, malignant and unspecified, including cysts and polyps.